ReviewClinical journal of the American Society of Nephrology : CJASN2013
Dabigatran and kidney disease: a bad combination.
Review in Clinical journal of the American Society of Nephrology : CJASN, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- The Impairment in Kidney Function in the Oral Anticoagulation Era. A Pathophysiological Insight.Cardiovascular drugs and therapy · 2021Pooled it
- Idarucizumab in Dabigatran-Treated Patients with Acute Ischemic Stroke Receiving Alteplase: A Systematic Review of the Available Evidence.CNS drugs · 2017Pooled it
- Anticoagulation Management: Current Landscape and Future Trends.Journal of clinical medicine · 2025Review
- Pharmacokinetics of Apixaban Among Peritoneal Dialysis Patients.Kidney medicine · 2023Article
- Physiologically-based pharmacokinetic modeling to predict drug-drug interactions of dabigatran etexilate and rivaroxaban in the Chinese older adults.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2023Article
- Article
- The use of anticoagulants in chronic kidney disease: Common point of view of cardiologists and nephrologists.Cardiology journal · 2020Review
- Pharmacogenomics of Novel Direct Oral Anticoagulants: Newly Identified Genes and Genetic Variants.Journal of personalized medicine · 2019Review
- Anticoagulant Related Nephropathy Induced by Dabigatran.Case reports in nephrology · 2018Article
- Anticoagulant-related nephropathy: a case report and review of the literature of an increasingly recognized entity.International urology and nephrology · 2017Review
- Article
- Dabigatran-Related Nephropathy in a Patient with Undiagnosed IgA Nephropathy.Case reports in nephrology · 2015Article
- Current and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatran.Vascular health and risk management · 2015Review
- Use of hemodialysis for the treatment of intracerebral hemorrhage in patients on dabigatran with normal renal function.Clinical nephrology. Case studies · 2014Article
- Gene polymorphism as a cause of hemorrhagic complications in patients with non-valvular atrial fibrillation treated with oral vitamin K-independent anticoagulants.Therapeutic advances in cardiovascular diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dabigatran is an oral direct thrombin inhibitor widely used to prevent and treat various thromboembolic complications. An advantage of this agent over other anticoagulants is that routine laboratory monitoring and related dose adjustments are considered unnecessary. A major disadvantage is the absence of a reliable means of reversing its anticoagulant effect. After U.S. Food and Drug Administration approval, recently emerged data suggest a higher bleeding risk with dabigatran, especially in the elderly. Clinicians are thus faced with caring for patients with serious bleeding events without readily available tests to measure drug levels or the anticoagulant effects of dabigatran and without effective antidotes to rapidly reverse the anticoagulant effect. On the basis of dabigatran's pharmacokinetic profile, hemodialysis and continuous renal replacement therapy have been used to remove dabigatran with the hope, still unproven, that this would rapidly reverse the anticoagulant effect and reduce bleeding in patients with normal and those with reduced kidney function. However, the best clinical approach to the patient with serious bleeding is not known, and the risks of placing a hemodialysis catheter in an anticoagulated patient can be substantial. This article reviews this issue, addressing clinical indications, drug pharmacokinetics, clinical and laboratory monitoring tests, and dialytic and nondialytic approaches to reduce bleeding in dabigatran-treated patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.